Table 2.
Characteristics and mortality due to COVID-19.
| Mortality | Univariate | MultivariateBinary Logistic Regression | |||||
|---|---|---|---|---|---|---|---|
| Yes (%) | No (%) | p-Value | OR with 95% CI | RR with 95% CI | p-Value | aOR with 95% CI | |
| Sex (M/F) | 50/20 | 103/82 | 0.022 * | 1.99 (1.10–3.61) | 1.67 (1.06–2.64) | 0.036 | 2.09 (1.05–4.18) |
| Age (median, IQR) | 72.5 (15) | 61.0 (24) | <0.001 ± | - | - | <0.001 | 1.06 (1.03–1.09) |
| Atrial Fibrillation | 33 (47.1) | 49 (26.5) | 0.002 * | 2.48 (1.40–4.39) | 1.88 (1.28–2.78) | 0.201 | 1.64 (0.77–3.48) |
| Respiratory Disease | 14 (20.0) | 18 (9.7) | 0.027 * | 2.32 (1.08–4.97) | 1.74 (1.11–2.74) | 0.297 | 1.61 (0.66–3.95) |
| Coronary Disease | 20 (28.6) | 30 (16.2) | 0.027 * | 2.07 (1.08–3.96) | 1.64 (1.08–2.49) | 0.808 | 0.90 (0.39–2.09) |
| Diabetes | 18 (25.7) | 35 (18.9) | 0.233 * | 1.48 (0.77–2.84) | 1.32 (0.85-2.05) | 0.758 | 0.87 (0.41–1.91) |
| Neoplasia | 10 (14.3) | 19 (10.3) | 0.367 * | 1.46 (0.64-3.31) | 1.30 (0.75–2.24) | 0.395 | 0.67 (0.26–1.70) |
| Hyperlipidemia | 30 (42.9) | 83 (44.9) | 0.773 * | 0.92 (0.53–1.61) | 0.94 (0.63–1.41) | 0.008 | 0.38 (0.19–0.78) |
| Hypertension | 52 (74.3) | 90 (48.6) | <0.001 * | 3.05 (1.66–6.60) | 2.30 (1.43–3.70) | 0.198 | 1.67 (0.77–3.62) |
| β-Thalassemia Heterozygotes | 20 (28.6) | 25 (13.5) | 0.005 * | 2.56 (1.31–4.99) | 1.87 (1.24–2.80) | 0.010 | 2.79 (1.28–6.09) |
* Chi-square test, ± Mann–Whitney test; Bold is for the statistically significant results (p-value < 0.05).